BRAF V600E Mutation in Papillary Thyroid Cancer and Its Effect on Postoperative Radioiodine ( 131 I) Therapy: Should We Modify Our Therapeutic Strategy?

Clinical Significance of PEAK1 Expression and BRAF V600E Mutation in Papillary Thyroid Cancer

“…Some studies reported that the BRAF mutation status may not impact the clinical response to I 131 therapy for PTC patients, and the response to I 131 therapy was not significantly different between the BRAFV600E mutation and the wild-type groups ( 9 ). However, Domínguez Ayala et al ( 10 ) reported that the mutation of the BRAF V600E gene is related with greater resistance to postoperative treatment with I 131 since the onset of the disease. In our study, BRAF mutation was not related with the response to I 131 therapy.…”